The use of novel PP2A activators in combination with PARP inhibitor for the treatment of high-grade serous ovarian cancer
Armstrong, A.J, Joseph, P, Nagaraj, A.B, Nagel, C.I, Nakayama, J, Waggoner, S.E, Zanotti, K.M, DiFeo, A, Narla, G
Published in Gynecologic oncology (01.06.2017)
Published in Gynecologic oncology (01.06.2017)
Get full text
Journal Article
The wnt/β-catenin-specific inhibitor, ICG-001, proves effective for the treatment of high-grade serous ovarian cancer in murine models through the targeting of cancer initiating cells
Connor, R.S, Nagaraj, A.B, Joseph, P, Mantilla, S, Kovalenko, O, Nagel, C.I, Nakayama, J, Waggoner, S.E, Zanotti, K.M, Singh, S, DiFeo, A
Published in Gynecologic oncology (01.06.2017)
Published in Gynecologic oncology (01.06.2017)
Get full text
Journal Article
Small molecule activators of protein phosphatase 2A for the treatment of endometrial cancer
Joseph, P, Nagaraj, A.B, Armstrong, A, Resnick, K.E, Zanotti, K.M, Waggoner, S.E, Narla, G, DiFeo, A
Published in Gynecologic oncology (01.04.2015)
Published in Gynecologic oncology (01.04.2015)
Get full text
Journal Article
The use of novel PP2A activators in combination withPARP inhibitor for the treatment of high-grade serous ovarian cancer
Armstrong, A.J., Joseph, P., Nagaraj, A.B., Nagel, C.I., Nakayama, J., Waggoner, S.E., Zanotti, K.M., DiFeo, A., Narla, G.
Published in Gynecologic oncology (01.06.2017)
Published in Gynecologic oncology (01.06.2017)
Get full text
Journal Article